anaemia
Human recombinant erythropoietin (rHuEpo) that is used for the treatment of the chemotherapy-induced anaemia in cancer patients was shown to cause detrimental effects on the course of disease due to increased adverse events inflicting patient's survival, potentially related to rHuEpo-induced cancer progression.
Human recombinant <span class="gene" id="23077460-1-18-32">erythropoietin</span> (<span class="gene" id="23077460-1-34-40">rHuEpo</span>) that is used for the treatment of the chemotherapy-induced <span class="disease" id="23077460-1-101-108">anaemia</span> in cancer patients was shown to cause detrimental effects on the course of disease due to increased adverse events inflicting patient's survival, potentially related to <span class="gene" id="23077460-1-278-284">rHuEpo</span>-induced cancer progression.